Reporting from: – 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004 – New England Journal of Medicine – Journal of Clinical Oncology ̵
Reporting from:
– 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, June 5-8, 2004
– New England Journal of Medicine
– Journal of Clinical Oncology
– European Journal of Cancer
– Science
– PNAS
In this edition:
Articles in the New England Journal of Medicine on metastatic colorectal cancer are reviewed by George Canellos, who discusses treatment with bevacizumab combined with an irinotecan regimen. Robert Mayer comments on the prospects for developing combinations of targeted therapies for colorectal cancer.
John Hainsworth presented his results at the ASCO conference on treatment of patients with advanced renal cancer with two targeted therapies combined: elotinib and bevacizumab.
The superiority of exemestane over tamoxifen for metastatic breast cancer
was claimed by Robert Paridaens during the New Orleans Meeting in the light of his phase III study findings.
Michele Saunders discusses her New England Journal editorial about two studies in which cisplatin has been added to radiotherapy for treating patients with head and neck cancer.
…
Related Episodes
David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trial
CHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China. Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA
Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income Countries
CHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology. Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.
John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial Therapy
CHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial therapy.Findings were reported at the 2026 Annual Meeting of the American Society of Clinical Oncology.Peter Goodwin got the details from first author John Mascarenhas MD, Professor of Medicine and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Tisch Cancer Institute, Icahn School of Medicine, in Mount Sinai, New York, NY.